Applicant, as named in the Orange Book

Bristol

Next listed expiry: Onureg on 3 Jun 2030. 9 products with live protection, 0 without.

Products with listed protection

Drug	Ingredient	NDA	Earliest generic entry	Basis
Onureg · 2 strengths azacitidine	azacitidine	214120	3 Jun 2030	patent
Pomalyst · 4 strengths pomalidomide	pomalidomide	204026	21 Dec 2031	patent
Evotaz atazanavir sulfate; cobicistat	atazanavir sulfate; cobicistat	206353	6 Oct 2032	patent
Camzyos · 5 strengths mavacamten	mavacamten	214998	28 Apr 2036	patent
Augtyro · 2 strengths repotrectinib	repotrectinib	218213	24 Jul 2036	patent, carve-out possible
Zeposia · 3 strengths ozanimod hydrochloride	ozanimod hydrochloride	209899	30 Sep 2038	patent
Eliquis Sprinkle apixaban	apixaban	220073	22 May 2041	patent
Sotyktu deucravacitinib	deucravacitinib	214958	11 Feb 2043	patent
Krazati adagrasib	adagrasib	216340	21 Aug 2043	patent

Recent events

Pomalyst · Generic approved · ANDA 210245, MsnApproved 2 Sep 2026Detected 25 Oct 2026
Pomalyst · Generic approved · ANDA 210232, SpilApproved 31 Aug 2026Detected 25 Oct 2026
Pomalyst · Generic approved · ANDA 220741, SandozApproved 31 Aug 2026Detected 25 Oct 2026
Pomalyst · Generic approved · ANDA 219718, CiplaApproved 31 Aug 2026Detected 25 Oct 2026
Pomalyst · Generic approved · ANDA 213234, Dr ReddysApproved 31 Aug 2026Detected 25 Oct 2026